The combination of Tadalafil, silodosin, and paroxetine is effective in the treatment of premature ejaculation.

A Randomized, Double-Blind, Placebo Controlled Phase 2 Study to assess the safety and efficacy of a combination of Tadalafil, Silodosin and Paroxetine HCI CR use concurrently for Premature Ejaculation (PE)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202211709374727

Enrollment

Registered

2022-11-29

Start date

2022-11-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental and Behavioural Disorders

Interventions

treatment arm

control arm

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Ages 18-49 (include 18 and 49) years old male 2) Have sexual intercourse with female on a regular basis (at least twice a week) 3) Intra-vaginal Latency Time (IVLT) < 1 min consistently for at least one year

Exclusion criteria

Exclusion criteria: 1) Use of Certain medications/agents (e.g., Nitrates, other antihypertensive, grapefruit juice) 2) Known hypersensitivity to study agents 3) Current or history of kidney disease. GFR< 50 4) Recent History of MI 5) History of Erectile dysfunction

Design outcomes

Primary

Measure	Time frame
IELT at 3 weeks and 5 weeks compared with placebo	—

Secondary

Measure	Time frame
Clinical Global Impression of Change	—

Countries

Nigeria

Contacts

Public Contactsterling mgbekwe

clinical research associate

sterling.mgbekwe@zyvranpharma.com+17144871901

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026